Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Coronavirus Pathology is frequently associated with both diabetes mellitus and metabolic syndrome. In particular, results of observational studies and meta-analyzes configure diabetes as one of the main risk factors for the development of complications and unfavorable course of SARS (Severe Acute Respiratory Syndrome) and MERS (Middle East Respiratory Syndrome), the syndromes caused respectively by SARS- VOC coronavirus and MERS-COV coronavirus. The available data confirm this association also in the clinical picture of the infection supported by SARS-COV 2 (COVID-19). In the epidemic outbreak that erupted at the beginning of 2020 in the Lombardy Region, about two thirds of the patients who died from COVID-19 were affected by diabetes mellitus. COVID-19 occurs in 70% of cases with an inflammatory pathology of the airways that can be fed by a cytokine storm and result in severe respiratory failure (10% cases) and death (5%). At the moment, the mainly involved pathophysiological molecular mechanisms are not clearly defined. It has been hypothesized that the transmembrane glycoprotein type II CD26, known for the enzyme activity Dipeptilpeptidase 4 exerted by its extracellular domain, may play a fundamental role in this process. In addition, it is considerably expressed at the parenchyma and lung interstitium level and carries out both systemic and paracrine enzymatic activity, modulating the activity of various proinflammatory cytokines, growth factors and vasoactive peptides at the level of the deep respiratory tract. The pulmonary parenchyma and the interstitium express significantly the Dipeptilpeptidase 4 protein, which in the Middle East Respiratory Syndrome favors the entry of the virus into the cells, thus allowing the virus to replicate within the cells and thus spread throughout the cell inside the organism. Dipeptilpeptidase 4 regulates the function of bioactive peptides and above all of cytokines, vasoactive peptides and chemokines present at the level of the mesothelium, of the deep respiratory tract (alveolar epithelium and alveolar bronchus), of endothelial and immune cells triggering the inflammatory storm. In line with this evidence, it has been hypothesized that acute respiratory disease from Coronavirus may depend on the massive localization of Dipeptilpeptidase 4 in lung tissue. Furthermore, the involvement of Dipeptilpeptidase 4 in other chronic respiratory diseases has been demonstrated. Starting from these observations we hypothesized that the selective blockade of Dipeptilpeptidase 4 can favorably modulate the pulmonary inflammatory response in the subject affected by COVID-19. Among the drugs that selectively block Dipeptilpeptidase 4, the one with greater affinity precisely for Dipeptilpeptidase 4 is Sitagliptin.
Description: Clinical evaluation of physiological parameter "cough" associated with acute lung disease from the beginning of the study to the end of the study
Measure: Clinical parameter of acute lung disease Time: 1 monthDescription: Variation of the clinical parameter "oxygen saturation by the use of a pulse oximeter" of acute lung disease from the beginning of the study to the end of the study
Measure: Clinical parameter of acute lung disease Time: 1 monthDescription: Variation of the clinical parameter "body temperature" of acute lung disease from the beginning of the study to the end of the study
Measure: Clinical parameter of acute lung disease Time: 1 monthDescription: Variation of the clinical parameter "PaO2/FiO2" of acute lung disease from the beginning of the study to the end of the study
Measure: Clinical parameter of acute lung disease Time: 1 monthDescription: Variation of the clinical parameter "respiratory rate" of acute lung disease from the beginning of the study to the end of the study
Measure: Clinical parameter of acute lung disease Time: 1 monthDescription: Variation of the clinical parameter "need for ventilator support" of acute lung disease from the beginning of the study to the end of the study
Measure: Clinical parameter of acute lung disease Time: 1 monthDescription: Variation of the clinical parameter "duration in days of ventilator support, duration in days of oxygen therapy, duration in days of hospitalization, duration in days in the Intensive Care Unit, total length of stay in hospital" of acute lung disease from the beginning of the study to the end of the study
Measure: Clinical parameter of acute lung disease Time: 1 monthDescription: Death of the patient during hospitalization due to COVID19
Measure: Death Time: 1 monthDescription: Variation of the biochemical parameter "reactive C protein" of acute lung disease from the beginning of the study to the end of the study
Measure: Biochemical parameter of acute lung disease Time: 1 monthDescription: Variation of the biochemical parameter "blood count with formula" of acute lung disease from the beginning of the study to the end of the study
Measure: Biochemical parameter of acute lung disease Time: 1 monthDescription: Variation of the biochemical parameter "erythrocyte sedimentation rate" of acute lung disease from the beginning of the study to the end of the study
Measure: Biochemical parameter of acute lung disease Time: 1 monthDescription: Variation of the biochemical parameter "blood gas analysis" of acute lung disease from the beginning of the study to the end of the study
Measure: Biochemical parameter of acute lung disease Time: 1 monthDescription: Variation of the biochemical parameter "LDH" of acute lung disease from the beginning of the study to the end of the study
Measure: Biochemical parameter of acute lung disease Time: 1 monthDescription: Variation of the biochemical parameter "fasting blood glucose" of acute lung disease from the beginning of the study to the end of the study
Measure: Biochemical parameter of acute lung disease Time: 1 monthDescription: Variation of the clinical parameter "chest X ray" of acute lung disease from the beginning of the study to the end of the study
Measure: Clinical parameter of acute lung disease Time: 1 monthAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports